Company Overview

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology therapeutics based on proprietary self-delivering RNA interference (RNAi) technology. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on enhancing immune cell activity against cancer. Phio’s core platform, known as INTASYL, is designed to silence specific genes involved in immune suppression without requiring specialized delivery vehicles. The company’s principal revenue activity historically has been derived from financing activities and collaboration-related arrangements rather than commercial product sales, as it does not currently market approved therapies.

The company traces its origins to RXi Pharmaceuticals Corporation, which was founded in 2011 following the merger of Galena Biopharma’s RNAi assets with RXi Pharmaceuticals. The business later rebranded as Phio Pharmaceuticals Corp. to reflect its immuno-oncology focus. Phio has positioned itself around the potential advantages of self-delivering RNAi compounds, including localized administration, reduced delivery complexity, and the ability to enhance adoptive cell therapies such as tumor-infiltrating lymphocytes (TILs) and CAR-T therapies. Public disclosures in SEC filings and corporate presentations indicate that the company primarily targets oncology researchers, clinical collaborators, and biotechnology partners developing cell-based cancer therapies.

Business Operations

Phio’s operations are centered on the development of RNAi therapeutics using its INTASYL platform. The company’s principal business activities include preclinical research, clinical development, intellectual property management, and strategic collaborations in immuno-oncology. Its therapeutic candidates are designed to suppress genes that inhibit immune cell activation, with programs focused on enhancing T-cell function in the tumor microenvironment. Clinical and preclinical programs have included compounds targeting PD-1 and other immune-regulatory pathways intended for use in adoptive cell therapy applications.

The company primarily operates in the United States, with research and corporate activities historically concentrated in Massachusetts. Phio has collaborated with academic institutions and biotechnology organizations to evaluate the use of its RNAi compounds in cell therapy manufacturing and cancer treatment strategies. The company maintains intellectual property related to self-delivering RNAi chemistry and therapeutic applications. As a clinical-stage company, Phio does not currently report diversified operating segments or recurring commercial revenue streams in publicly available filings.

Strategic Position & Investments

Phio’s strategic direction has focused on expanding the applicability of its RNAi platform in immune-oncology and cell therapy enhancement. The company has emphasized partnerships and translational research initiatives aimed at integrating INTASYL compounds into next-generation cancer immunotherapies. Its development strategy has included investigator-sponsored studies and collaborations evaluating the use of RNAi-modified immune cells in solid tumors and hematologic cancers.

The company has historically invested in platform development, intellectual property expansion, and clinical-stage oncology programs rather than large-scale acquisitions. Publicly available information does not indicate significant subsidiary holdings or major acquisition activity comparable to larger biotechnology firms. Phio’s positioning within the emerging RNAi therapeutics sector places it among smaller biotechnology companies seeking to leverage gene-silencing technologies for immunotherapy applications. Data regarding large international investments or material portfolio company holdings is inconclusive based on available public sources.

Geographic Footprint

Phio Pharmaceuticals Corp. is headquartered in Marlborough, Massachusetts, United States, and its operational footprint is primarily concentrated in North America. The company’s clinical development, corporate management, and regulatory activities are largely U.S.-based, with interactions involving domestic research institutions, clinical investigators, and biotechnology collaborators.

Although the company does not maintain the broad international commercial infrastructure typical of larger pharmaceutical firms, its research collaborations and intellectual property strategy support participation in the broader global biotechnology market. Public disclosures indicate that its technologies may be evaluated through international scientific and clinical partnerships, though detailed information regarding substantial standalone operations in Europe, Asia-Pacific, or other regions remains limited in publicly available filings.

Leadership & Governance

Phio Pharmaceuticals Corp. is governed by a board of directors and executive leadership team focused on advancing clinical-stage immuno-oncology programs. The company’s leadership strategy, as described in corporate communications and investor materials, emphasizes disciplined capital allocation, translational oncology research, and the advancement of differentiated RNAi technologies for cancer treatment.

Key executives and leadership figures include:

• Robert Bitterman – President and Chief Executive Officer
• Alyssa Farina – Chief Financial Officer
• Gerrit Dispersyn, Ph.D. – Chief Development Officer
• Thomas Equels – Chairman of the Board

The leadership team has communicated a strategic focus on leveraging the company’s RNAi platform to improve the effectiveness of cell-based immunotherapies while pursuing collaborative development opportunities within the oncology sector.